White J E, Perkins P J, Evans E G
Department of Dermatology, Royal South Hants Hospital, Southampton, U.K.
Br J Dermatol. 1991 Sep;125(3):260-2. doi: 10.1111/j.1365-2133.1991.tb14752.x.
A new orally active antifungal agent, terbinafine, was used in the treatment of tinea pedis ('dry type' or moccasin type) and tinea manuum. Fifty-three adults over the age of 16 years with fungal infections of the feet and/or hands were treated with either oral terbinafine, 250 mg, or placebo, once daily for 2 weeks. The diagnosis of fungal infection was confirmed by examination of skin scrapings by microscopy and culture. Of these, 28 patients were evaluable for efficacy. At 8 weeks, 12 out of 14 (86%) patients who received terbinafine were mycologically negative (microscopy and culture) compared to one out of 14 (7%) patients on placebo (P less than 0.001, Fishers exact test, one-sided). At the end of the study 71% of patients in the terbinafine group were judged to have received effective therapy compared to 0% in the placebo group (P less than 0.001). Terbinafine was well tolerated, and more side-effects were seen in the placebo group.
一种新型口服活性抗真菌药物特比萘芬被用于治疗足癣（“干性”或“拖鞋型”）和手癣。53名16岁以上足部和/或手部真菌感染的成年人，分别接受250毫克口服特比萘芬或安慰剂治疗，每日一次，持续2周。通过显微镜检查和培养皮肤刮屑确诊真菌感染。其中，28名患者可进行疗效评估。8周时，接受特比萘芬治疗的14名患者中有12名（86%）真菌学检查呈阴性（显微镜检查和培养），而接受安慰剂治疗的14名患者中只有1名（7%）呈阴性（P<0.001，Fisher精确检验，单侧）。研究结束时，特比萘芬组71%的患者被判定接受了有效治疗，而安慰剂组为0%（P<0.001）。特比萘芬耐受性良好，安慰剂组出现的副作用更多。
